Drug Trial Radar · NCT05359445
IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint Inhibitor
Last checked: Nov 19, 2026Latest source record: Apr 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
95
Planned (sponsor's estimate)
Start
May 19, 2022
Primary completion
Mar 18, 2026
Study completion Dec 2029
Sponsor
- Lead sponsor
- Immatics Biotechnologies GmbHIndustry
- Sponsor type
- Industry
- First posted
- May 3, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to evaluate the safety, tolerability and initial anti-tumor activity of IMA401 as monotherapy or in combination with checkpoint inhibitor in patients with recurrent and/or refractory solid tumors. Patients' HLA status and expression of the MAGE-A4 and/or MAGE-A8 target in the tumor must be confirmed. Primary objective: * To determine the maximum tolerated dose and/or recommended dose for extension for IMA401 as monotherapy and in combination with pembrolizumab Secondary objectives: * To characterize the safety and tolerability of IMA401 as monotherapy and in combination with pembrolizumab * To evaluate initial anti-tumor activity of IMA401 as monotherapy and in combination with pembrolizumab * To describe the pharmacokinetics of IMA401 as monotherapy and in combination with pembrolizumab
Conditions
- Refractory Cancer
- Recurrent Cancer
- Solid Tumor, Adult
- Cancer
Interventions
IMA401 (Phase Ia)Biological
Intravenous infusions in escalating dose levels
Pembrolizumab (Phase Ia)Biological
Intravenous infusions in escalating dose levels for combination of IMA 401 and Pembrolizumab
IMA 401 (Phase Ib)Biological
Treatment at recommended dose for extension (RDE)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of patients with dose limiting toxicitiesTime frame: 44 months
Locations
21 sites in 1 country. Site status is shown where the registry gives one.
Charité Universitaetsmedizin Berlin KöR, Klinik fuer Haematologie und Onkologie
Berlin, Germany
Universitaetsklinikum Freiburg, Zentralklinikum, Klinik fuer Innere Medizin I
Freiburg im Breisgau, Baden-Wurttemberg, Germany
Universitaetsklinikum Heidelberg AöR, Nationales Zentrum fuer Tumorkrankheiten
Heidelberg, Baden-Wurttemberg, Germany
Thoraxklinik Heidelberg gGmbH, Studienzentrum Thoraxonkologie
Heidelberg, Baden-Wurttemberg, Germany
Universitaetsklinikum Tuebingen AöR, Comprehensive Cancer Center Tuebingen
Tübingen, Baden-Wurttemberg, Germany
Universitaetsklinikum Ulm AöR, ECTU-Early clinical Trials Unit Universitaetsklinikum Ulm Comprehensive Cancer Center Ulm_CCCU
Ulm, Baden-Wurttemberg, Germany
Universitaetsklinikum Erlangen AöR, Interdisciplinary Clinical Trial Unit with ECTU
Erlangen, Bavaria, Germany
Klinikum rechts der Isar der TU Muenchen AöR, Klinik und Poliklinik fuer Innere Medizin III
Munich, Bavaria, Germany
Klinikum Nuernberg, Klinik fuer Innere Medizin 5, Abteilung Onkologie/Haematologie
Nuremberg, Bavaria, Germany
Universitaetsklinikum Regensburg AöR, Klinik fuer Innere Medizin 3
Regensburg, Bavaria, Germany
Universitaetsklinikum Wuerzburg AöR, Interdisziplinaeres Studienzentrum mit ECTU
Würzburg, Bavaria, Germany
Goethe Universitaetsklinikum Frankfurt AöR, Medizinische Klinik II
Frankfurt am Main, Hesse, Germany
Medizinische Hochschule Hannover, Klinik fuer Haematologie, Haemostaseologie, Onkologie und Stammzelltransplantation
Hanover, Lower Saxony, Germany
Universitätsklinikum Bonn AöR, Medizinische Klinik IIII
Bonn, North Rhine-Westphalia, Germany
Marien Hospital Duesseldorf GmbH, Klinik fuer Onkologie/Haematologie und Palliativmedizin
Düsseldorf, North Rhine-Westphalia, Germany
Universitaetsklinikum Muenster AöR, Medizinische Klinik A
Münster, North Rhine-Westphalia, Germany
Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöR, III. Medizinische Klinik
Mainz, Rhineland-Palatinate, Germany
Klinikum Chemnitz gGmbH, Klinik für Innere Medizin III
Chemnitz, Saxony, Germany
Universitaetsklinikum C. - G. - Carus Dresden, Technische Universitaet Dresden AöR, NCT/UCC Early Clinical Trial Unit
Dresden, Saxony, Germany
Universitaet Leipzig, Universitaeres Krebszentrum Leipzig (UCCL)
Leipzig, Saxony, Germany
Universitaetsklinikum Schleswig- Holstein, Campus Kiel, Medizinische Klinik II Haematologie und Onkologie, Karl-Lennert Tumorzentrum
Kiel, Schleswig-Holstein, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.